Antihypertensive therapy debate: contribution from the Shanghai Trial Of Nifedipine in the Elderly (STONE)

Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
P Hamet, L Gong

Abstract

In 1993, a number of influential bodies reported the results of consensus conferences on the management of hypertension, including the World Health Organization/International Society of Hypertension, the fifth United States Joint National Committee (JNC-V), the British Hypertension Society, the Canadian Hypertension Society (CHS) and the New Zealand National Advisory Committee. Most of these guidelines were in general agreement. The most significant difference was in the choice of first-line agents, whether to use only beta-blockers or thiazides (JNC-V/CHS) or to use any of the five major classes of antihypertensive agents. At present, this is the only placebo-controlled trial on newer classes of medications for which results are available. The trial has both strengths and weaknesses. Among the strengths of this trial is the comparability of the subjects in both arms and the robustness of the results. STONE does at least suggest that outcomes with newer agents like long-acting nifedipine are comparable to outcomes in major clinical trials in the elderly using diuretics and beta-blockers.

Citations

Nov 7, 1996·The American Journal of Cardiology·F H Messerli
Jul 14, 2001·Journal of the American College of Cardiology·K KarioT G Pickering
Dec 10, 1999·Journal of the American College of Cardiology·R P Mason
Aug 8, 2001·Journal of Evaluation in Clinical Practice·J I Robertson
Jun 1, 1997·Australian and New Zealand Journal of Medicine·P L Thompson, P E Langton
Sep 1, 2006·International Journal of Clinical Practice·S Bangalore, F H Messerli
Jan 25, 2002·Current Controlled Trials in Cardiovascular Medicine·Lutgarde ThijsUNKNOWN On behalf of the Systolic Hypertension in Europe Investigators
Jan 5, 2002·The American Journal of Geriatric Cardiology·Gastone Leonetti, Alberto Zanchetti
Feb 15, 2005·International Journal of Clinical Practice·C-C ChouM-H Chuang
Dec 29, 2015·Journal of Cardiac Failure·Michael W Rich
Dec 1, 2012·Kidney International Supplements
Jul 29, 2009·The American Journal of Medicine·Michael A Chen
Oct 9, 2007·International Journal of Cardiology·Tsung O Cheng
Sep 12, 2006·The Medical Clinics of North America·Michael W Rich
Apr 29, 2005·The Journal of Clinical Hypertension·William J Elliott, Armin Bandari
Jun 5, 2013·The Journal of Clinical Hypertension·Yong WeiJiguang Wang
Jan 4, 2013·Diabetes/metabolism Research and Reviews·Ji-Guang Wang, Yan Li
Jan 4, 2013·Diabetes/metabolism Research and Reviews·Gadi Shlomai, Ehud Grossman
May 26, 1999·Current Problems in Cardiology·M FreherM Gheorgiade
Jan 5, 2002·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·M ShinagawaF Halberg
Mar 1, 1997·Lancet·J McMurray, D Murdoch
Nov 20, 1998·The American Journal of Cardiology·F H Messerli, E Grossman
Jun 1, 2012·International Journal of Cardiology·Dingliang ZhuUNKNOWN trial investigators
Jul 4, 2016·Annals of Global Health·Joshua D Bundy, Jiang He
Dec 1, 2001·Progress in Cardiovascular Diseases·J Muntwyler, F Follath

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.